CL2018003417A1 - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
CL2018003417A1
CL2018003417A1 CL2018003417A CL2018003417A CL2018003417A1 CL 2018003417 A1 CL2018003417 A1 CL 2018003417A1 CL 2018003417 A CL2018003417 A CL 2018003417A CL 2018003417 A CL2018003417 A CL 2018003417A CL 2018003417 A1 CL2018003417 A1 CL 2018003417A1
Authority
CL
Chile
Prior art keywords
new compounds
neutrófilos
elastasa
humana
therapy
Prior art date
Application number
CL2018003417A
Other languages
English (en)
Inventor
Elisabetta Armani
Carmelida Capaldi
Jonathan Mark Sutton
Robert Andrew Heald
Andrew Stephen Robert Jennings
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2018003417A1 publication Critical patent/CL2018003417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

DERIVADOS DE IMIDAZOLONA QUE TIENEN PROPIEDADES INHIBITORIAS DE LA ELASTASA DE NEUTRÓFILOS HUMANA, Y SU USO EN TERAPIA.
CL2018003417A 2016-05-31 2018-11-30 Nuevos compuestos. CL2018003417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172196 2016-05-31

Publications (1)

Publication Number Publication Date
CL2018003417A1 true CL2018003417A1 (es) 2019-01-18

Family

ID=56096538

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003417A CL2018003417A1 (es) 2016-05-31 2018-11-30 Nuevos compuestos.

Country Status (25)

Country Link
US (2) US9802919B1 (es)
EP (1) EP3464273B9 (es)
JP (1) JP6990663B2 (es)
KR (1) KR102404031B1 (es)
CN (1) CN109311850B (es)
AR (1) AR108610A1 (es)
AU (1) AU2017272405C1 (es)
BR (1) BR112018074608B1 (es)
CA (1) CA3020435A1 (es)
CL (1) CL2018003417A1 (es)
CO (1) CO2018012479A2 (es)
EA (1) EA036456B1 (es)
GE (1) GEP20207130B (es)
IL (1) IL263089B (es)
MX (1) MX2018014145A (es)
MY (1) MY195210A (es)
NZ (1) NZ747313A (es)
PE (1) PE20190176A1 (es)
PH (1) PH12018502242A1 (es)
SA (1) SA518400429B1 (es)
SG (2) SG10201912143UA (es)
TW (1) TWI738786B (es)
UA (1) UA123109C2 (es)
WO (1) WO2017207430A1 (es)
ZA (1) ZA201806743B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202108571A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
JP2023500182A (ja) 2019-09-17 2023-01-05 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
EP4252850A3 (en) 2020-04-16 2023-11-15 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
WO2023115043A1 (en) * 2021-12-16 2023-06-22 Orixa Therapeutics Llc Small molecule inhibitors of pr3 and hne and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
EP1435353A4 (en) 2001-10-03 2006-01-04 Nippon Soda Co NEW HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
WO2011039528A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
JP2013177318A (ja) 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
RU2638537C2 (ru) * 2012-07-12 2017-12-14 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибирование ферментов
RS58129B1 (sr) 2012-12-18 2019-02-28 Chiesi Farm Spa Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za tretman respiratornih bolesti
JP5799117B2 (ja) * 2013-02-05 2015-10-21 大日本住友製薬株式会社 ウラシル誘導体からなる医薬
CN105873933A (zh) 2013-12-16 2016-08-17 奇斯药制品公司 作为人中性白细胞弹性蛋白酶抑制剂的四氢三唑并嘧啶衍生物
US9409870B2 (en) 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds

Also Published As

Publication number Publication date
SG10201912143UA (en) 2020-02-27
CO2018012479A2 (es) 2018-12-14
EA201892714A1 (ru) 2019-05-31
AU2017272405A1 (en) 2018-11-22
IL263089B (en) 2021-12-01
BR112018074608B1 (pt) 2024-01-23
JP2019520313A (ja) 2019-07-18
KR20190015232A (ko) 2019-02-13
JP6990663B2 (ja) 2022-01-13
MX2018014145A (es) 2019-03-11
US10023558B2 (en) 2018-07-17
WO2017207430A1 (en) 2017-12-07
EP3464273B9 (en) 2020-10-21
UA123109C2 (uk) 2021-02-17
BR112018074608A2 (pt) 2019-03-19
KR102404031B1 (ko) 2022-06-02
AU2017272405C1 (en) 2021-01-14
ZA201806743B (en) 2020-02-26
IL263089A (en) 2018-12-31
CA3020435A1 (en) 2017-12-07
PE20190176A1 (es) 2019-02-01
US9802919B1 (en) 2017-10-31
TWI738786B (zh) 2021-09-11
GEP20207130B (en) 2020-07-10
TW201808934A (zh) 2018-03-16
CN109311850A (zh) 2019-02-05
EP3464273A1 (en) 2019-04-10
PH12018502242A1 (en) 2019-08-19
NZ747313A (en) 2020-01-31
MY195210A (en) 2023-01-11
EP3464273B1 (en) 2020-04-08
US20180009787A1 (en) 2018-01-11
SG11201809671PA (en) 2018-12-28
SA518400429B1 (ar) 2021-09-22
AR108610A1 (es) 2018-09-05
CN109311850B (zh) 2021-11-19
AU2017272405B2 (en) 2020-09-10
EA036456B1 (ru) 2020-11-12

Similar Documents

Publication Publication Date Title
CY1121831T1 (el) Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk
CL2018003417A1 (es) Nuevos compuestos.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
IL273839A (en) Benzimidazole derivatives and their uses
DK3606926T3 (da) Heteroaromatiske forbindelser anvendelige i terapi
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
BR112016018371A2 (pt) derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo
EP3400209A4 (en) ASCOCHLORIN DERIVATIVE AND ITS USE AS AMPK ACTIVATOR
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas